Trials / Not Yet Recruiting
Not Yet RecruitingNCT07396818
Kamlanoflast In Amyotrophic Lateral Sclerosis
A Trial of Kamlanoflast In Patients With Amyotrophic Lateral Sclerosis
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Inflammasome Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.
Conditions
- ALS (Amyotrophic Lateral Sclerosis)
- ALS
- Neuro-Degenerative Disease
- Neuro-Degenerative Diseases
- Motor Neuron Disease (MND)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kamlanoflast | Low dose Kamlanoflast by oral administration |
| DRUG | Kamlanoflast | High dose Kamlanoflast by oral administration |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2026-02-09
- Last updated
- 2026-02-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07396818. Inclusion in this directory is not an endorsement.